HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking
CEO Mike Blue Said Histotripsy Will Deliver Clinical Value At A Sustainable Cost For The NHS
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.
